Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Conditions: Small Cell Lung Cancer Recurrent Interventions: Drug: Irinotecan Liposome; Drug: Anlotinib Sponsors: Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials